Fulgent Genetics Q2 revenue $153.6M (+790% YoY); acquires CSI Labs, invests in Helio Health and FF Gene Biotech

Fulgent Genetics, Inc.

Q2 revenue $153.6M (+790% YoY); ~1.6M billable tests (9x YoY); gross margin improved ~21pp YoY.
GAAP net income $79.8M ($2.59 EPS); non-GAAP net income $78.7M ($2.55 EPS); adjusted EBITDA $105.0M.
Core (NGS) revenue grew 296% YoY to $25.7M.
Acquisition of CSI Laboratories (cancer diagnostics) and commercial agreement with Helio Health via strategic investment.
Incremental controlling investment in Chinese JV FF Gene Biotech.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.